Valeant says can contain hit to dermatology, projects 2016 growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Upward Earnings Revisions to Drive Valeant (VRX) Higher - Guggenheim
December 17, 2015 7:13 AM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and $195 price target on Valeant Pharmaceuticals (NYSE: VRX) following yesterday's analyst day. The analyst thinks upwards consensus earnings revisions and multiple expansion will drive VRX shares higher
Chen commented, "Post VRX's Investor Day on 12/16/15, we think upwards... More
